In the Phase II KEYNOTE-100 study, the largest study to date of single-agent immunity checkpoint for recurrent ovarian cancer, higher PD-L1 expression on tumor cells, lymphocytes, and macrophages correlated with higher pembrolizumab monotherapy (anti-PD-L1) response (31). This evidence concerns the gene CD274 and neoplasm.